Cyfuse Biomedical K.K. (4892.T)
JPY 463.0
(2.89%)
JPY 463.0
(2.89%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 61.11 Million | 374.47 Million | 708.24 Million | 137.48 Million |
| Cost of Revenue | 23.36 Million | 132.98 Million | 137.64 Million | 70.46 Million |
| Gross Profit | 37.74 Million | 241.49 Million | 570.6 Million | 67.02 Million |
| Operating Expenses | 735.18 Million | 666.58 Million | 500.03 Million | 439.15 Million |
| Selling, General and Administrative Expenses | 351 Million | 346 Million | 500 Million | 439 Million |
| Research and Development Expenses | 375 Million | 303 Million | 266.49 Million | 242.59 Million |
| Other Expenses | 9.18 Million | 37.44 Million | 79.4 Million | 50.43 Million |
| Cost and Expenses | 758.54 Million | 799.56 Million | 637.67 Million | 509.62 Million |
| Operating Income | -697.43 Million | -425.08 Million | 70.56 Million | -372.13 Million |
| Interest Expense | 9.77 Million | 27.93 Million | 5.23 Million | 5.93 Million |
| Income Tax Expense | 3.02 Million | 2 Million | 2 Million | 2 Million |
| Earnings before Tax | -586.18 Million | -471.95 Million | 144.91 Million | -327.49 Million |
| Net Income | -589.21 Million | -473.96 Million | 142.9 Million | -329.5 Million |
| Earnings Per Share Basic | -75.42 | -177.67 | 285.52 | -46.12 |
| Earnings Per Share Diluted | -75.42 | -177.67 | 285.52 | -46.12 |
| Weighted Average Shares Outstanding | 7.81 Million | 2.66 Million | 500.5 Thousand | 7.14 Million |
| Weighted Average Shares Outstanding (Diluted) | 7.81 Million | 2.66 Million | 500.5 Thousand | 7.14 Million |
| Gross Margin | 0.62 | 0.64 | 0.81 | 0.49 |
| EBIT Margin | -8.81 | -0.94 | 0.24 | -2.10 |
| Profit Margin | -9.64 | -1.27 | 0.20 | -2.40 |
| EBITDA | -538.28 Million | -410.2 Million | 168.64 Million | -288.66 Million |
| Earnings Before Tax Margin | -11.41 | -1.14 | 0.10 | -2.71 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 7.29 Million | 10.74 Million | 31.38 Million | 61.11 Million | 11.45 Million | 11.2 Million |
| Cost of Revenue | 15.24 Million | 4.52 Million | 5.71 Million | 23.36 Million | 8.96 Million | 5.53 Million |
| Gross Profit | -7.94 Million | 6.21 Million | 25.66 Million | 37.74 Million | 2.49 Million | 5.66 Million |
| Operating Expenses | 211.06 Million | 236.16 Million | 194.89 Million | 735.18 Million | 167.04 Million | 197.18 Million |
| Selling, General and Administrative Expenses | 110.79 Million | 236 Million | 189 Million | - | 167 Million | 197 Million |
| Research and Development Expenses | 100.27 Million | 131.52 Million | 375 Million | - | 82 Million | 95.43 Million |
| Other Expenses | 1.83 Million | 11.06 Million | 117.7 Million | 120.99 Million | -7.74 Million | 718 Thousand |
| Cost and Expenses | 226.31 Million | 240.69 Million | 200.61 Million | 758.54 Million | 176 Million | 202.71 Million |
| Operating Income | -219.01 Million | -229.94 Million | -169.23 Million | -697.43 Million | -164.54 Million | -191.51 Million |
| Interest Expense | 2.41 Million | 2.07 Million | 2.4 Million | 9.77 Million | 2.38 Million | 2.41 Million |
| Income Tax Expense | 635 Thousand | 585 Thousand | 686 Thousand | 3.02 Million | 686 Thousand | 610 Thousand |
| Earnings before Tax | -222.3 Million | -223.69 Million | -53.94 Million | -586.18 Million | -169.29 Million | -195.9 Million |
| Net Income | -222.93 Million | -224.27 Million | -54.62 Million | -589.21 Million | -169.97 Million | -196.51 Million |
| Earnings Per Share Basic | -27.76 | -28.38 | -6.98 | - | -21.74 | -25.16 |
| Earnings Per Share Diluted | -27.76 | -28.38 | -6.98 | - | -21.74 | -25.16 |
| Weighted Average Shares Outstanding | 8.02 Million | 7.9 Million | 7.82 Million | 7.81 Million | 7.81 Million | 7.81 Million |
| Weighted Average Shares Outstanding (Diluted) | 8.02 Million | 7.9 Million | 7.82 Million | 7.81 Million | 7.81 Million | 7.81 Million |
| Gross Margin | -1.09 | 0.58 | 0.82 | 0.62 | 0.22 | 0.51 |
| EBIT Margin | -28.77 | -20.62 | -1.64 | - | -14.57 | -17.27 |
| Profit Margin | -30.55 | -20.87 | -1.74 | -9.64 | -14.84 | -17.54 |
| EBITDA | -209.95 Million | -221.56 Million | -51.54 Million | - | -166.9 Million | -193.49 Million |
| Earnings Before Tax Margin | -30.01 | -21.40 | -5.39 | -11.41 | -14.36 | -17.10 |
2105
NXST
5371
0KCS
INDAG
000920